CC Chemicals · Performance chemicals · PFAS risk · Cyclical · Thesis updated July 2, 2026

A recovery story with little room for error

Chemours is a three-part chemical company, with TiO2 pigment, refrigerants, and advanced materials.
Q1 2026 was split: TSS Adjusted EBITDA rose 35%, while TT fell 64% and APM fell 84%.
Management still guides to $800 million to $900 million of full-year 2026 Adjusted EBITDA.
That guide depends on APM reaching a $30 million to $40 million quarterly EBITDA range in the second half.
The main risk is not demand alone. It is whether Chemours can keep its plants running and rebuild trust.

01 Running thesis

The guide is now the whole debate

Chemours has given investors a clearer path, but it is a hard one. Management kept its full-year 2026 Adjusted EBITDA guide at $800 million to $900 million. The bridge depends on a second-half rebound in Advanced Performance Materials, or APM, and Titanium Technologies, or TT.

The bull case starts with Thermal & Specialized Solutions, or TSS. In Q1 2026, TSS sales grew 22% year over year to $568 million, and Adjusted EBITDA rose 35% to $190 million. Management also pointed to sticky refrigerant pricing and strength in the Freon auto aftermarket.

The weak point is that the other two segments are barely contributing right now. In Q1 2026, TT Adjusted EBITDA fell 64% to $18 million, and APM Adjusted EBITDA fell 84% to $5 million. APM was hurt by a Washington Works outage that cost $25 million in the quarter.

Management says APM can get back to a $30 million to $40 million quarterly EBITDA range in the back half of 2026, helped by the best order book seen in several years. The market reaction after earnings was poor, which shows this is a prove-it story. Q2 and Q3 need to show real volume, margin, and pricing progress.

May 2026→Management kept full-year 2026 guidance and gave a clearer bridge. APM is expected to reach a $30 million to $40 million quarterly EBITDA range in the back half, but the plan requires strong execution.

May 2026▼The Q1 2026 filing showed a split company. TSS Adjusted EBITDA rose 35%, but TT fell 64% and APM fell 84% after a $25 million Washington Works outage impact.

Feb 2026→The 2025 10-K confirmed the Washington Works issue and added a balance sheet positive. Chemours planned a Taiwan land sale for about $360 million, with proceeds aimed at debt reduction.

Feb 2026▼Q4 2025 commentary showed that operating problems were not over. Management guided near-zero Q1 profitability for TT and APM, while still expecting a full-year recovery.

Nov 2025▼The Q3 2025 call raised questions about how clearly management was explaining plant problems. The core issue became whether disruptions were one-time events or a deeper reliability problem.

Nov 2025▼The Q3 2025 filing showed severe profit pressure in TT and APM from operational disruption costs. TSS stayed strong, but it was masking weakness elsewhere.

Aug 2025→Chemours lowered 2025 Adjusted EBITDA guidance because of discrete operational issues in TT and APM. A New Jersey environmental settlement also reduced some PFAS uncertainty.

May 2025▲Management pointed to a Q2 rebound in TT and continued TSS strength. The dividend cut improved balance sheet flexibility, while future ore contract expirations were framed as a cash flow tailwind.

02 Business model

Big plants, big swings

Chemours makes performance chemicals used in paint, plastics, refrigeration, electronics, and industrial systems. It earns money by selling specialized products that customers need for color, cooling, heat control, low friction, and chemical resistance.

The model can work well when plants run smoothly and pricing holds. TSS is the current example. Opteon and Freon refrigerants are benefiting from demand and price strength, which made TSS the main profit base in Q1 2026.

The model breaks when production is disrupted or commodity-like pricing turns against Chemours. TT is exposed to the TiO2 pigment cycle, raw material costs, and pricing pressure. APM is tied to complex fluoropolymer production, where a plant outage can quickly erase profit.

Chemours is also trying to lower balance sheet risk. The company disclosed a planned Taiwan land sale for about $360 million, with proceeds aimed at debt reduction. That helps, but it does not fix the core operating question.

03 Product portfolio

What Chemours sells

Cash cow

TiO2 pigment

Titanium Technologies sells titanium dioxide, a white pigment used to add whiteness, brightness, and opacity to coatings and plastics. It can be profitable, but Q1 2026 showed how quickly pricing, volume, and costs can hurt results.

Growth engine

Opteon refrigerants

Opteon is part of the TSS refrigerant lineup. Strong demand for Opteon helped TSS grow Q1 2026 sales by 22% year over year.

Cash cow

Freon aftermarket products

Freon serves refrigeration and auto aftermarket needs. Management described pricing as sticky, which matters because TSS is carrying most of the profit load.

Option

Advanced fluoropolymer materials

APM sells high-end polymers that resist heat, chemicals, and friction, and can provide electrical insulation. This segment has upside if the order book converts, but Q1 2026 profit was only $5 million after the Washington Works outage.

Steady

Specialty solvents and propellants

These products sit inside Thermal & Specialized Solutions. They add breadth to the refrigerant business and serve industrial and specialty applications.

04 Business segments

Q1 mix hides profit concentration

Titanium Technologies41%declining

Thermal & Specialized Solutions41%growing fast

Advanced Performance Materials18%declining

Segment shares use Q1 2026 net sales: TT at $559 million, TSS at $568 million, and APM at $243 million. Sales were balanced between TT and TSS, but profit was not: TSS produced $190 million of segment Adjusted EBITDA while TT and APM were far weaker.

05 Risk factors

What could break the thesis

Second-half recovery misses

High impact · High odds

The 2026 guide depends on a sharp rebound in APM and better TT results. APM must move from $5 million of Q1 2026 Adjusted EBITDA to a $30 million to $40 million quarterly range in the second half. That leaves little room for delays, weak volume, or missed cost savings.

We watchQ2 2026 and Q3 2026 segment Adjusted EBITDA for APM and TT, especially whether APM reaches the $30 million to $40 million quarterly range.

Plant reliability problems continue

High impact · Medium odds

Chemours has had repeated operating issues in TT and APM. The Washington Works outage cost APM $25 million in Q1 2026, after earlier 2025 disruption costs. These events raise the risk that manufacturing fragility is a pattern, not a one-time issue.

We watchAny new outage disclosure, force majeure, production cut, or segment margin miss tied to plant downtime.

TSS profit concentration fades

High impact · Medium odds

TSS is the standout business. In Q1 2026, it generated $190 million of Adjusted EBITDA, far more than TT and APM combined. If refrigerant pricing or volume weakens before the other segments recover, consolidated profit could fall fast.

We watchTSS price, volume, and Adjusted EBITDA margin trends, with special focus on Opteon demand and Freon auto aftermarket pricing.

PFAS and water rules add liabilities

High impact · Medium odds

PFAS remains a major legal and regulatory overhang. In April 2024, the EPA set drinking water limits for several PFAS, including PFOA and PFOS at 4 parts per trillion and HFPO-DA, also called GenX, at 10 parts per trillion. Public water systems have five years to comply, which could increase cleanup and settlement costs.

We watchNew EPA enforcement actions, state settlements, reserve changes, and remediation cost disclosures.

European chemical rules tighten

Medium impact · Medium odds

Europe is moving on several rules that matter to Chemours. ECHA classified TFA as a Category 2 Reprotoxin in March 2024, and Germany has signaled interest in a legally binding classification that includes reprotoxicity. A new EU F-Gas rule also phases down HFCs by 2050.

We watchECHA committee opinions, German classification proposals, and Chemours commentary on European product restrictions.

06 Quick answers

In one breath

What does Chemours make?

Chemours makes performance chemicals. Its main products include TiO2 pigment for coatings and plastics, Opteon and Freon refrigerants, and advanced fluoropolymer materials.

Why is Chemours stock a prove-it story?

Management kept its 2026 Adjusted EBITDA guide at $800 million to $900 million even after weak Q1 results in TT and APM. Investors now need to see APM and TT recover in Q2 and Q3.

Which Chemours segment is strongest right now?

Thermal & Specialized Solutions is the clear strength. In Q1 2026, TSS sales grew 22% year over year and Adjusted EBITDA rose 35%.

What is the biggest near-term risk for Chemours?

The biggest near-term risk is execution. APM needs to recover from $5 million of Q1 2026 Adjusted EBITDA to a $30 million to $40 million quarterly range in the second half.